Last update:
Oncology news
Data-driven tool to help oncologists identify high-risk periods for metastatic breast cancer patients
Oncologists know that intensive treatment rarely helps patients in their final days, but recognizing when someone is entering that stage is difficult, especially in metastatic breast cancer, where an increasing number of ...
5 hours ago
0
2
Researchers identify medulloblastoma molecular groups using noninvasive MRI spectroscopy
Research by Stefan Blüml, Ph.D., and colleagues investigates the use of in vivo proton magnetic resonance spectroscopy (¹H-MRS) to identify medulloblastoma molecular subgroups before surgery, a noninvasive alternative to ...
6 hours ago
0
1
Pancreatic tumors use clotting pathway to build immune shields, study finds
Researchers at the Icahn School of Medicine at Mount Sinai have found that small populations of pancreatic cancer cells can create localized immune-protective niches that shield tumors from immune attack. The finding could ...
23 hours ago
0
61
New analysis points to low overdiagnosis in breast cancer screening
When women take part in breast cancer screening, they are informed that screening may detect cancers that would never have caused symptoms or problems during their lifetime. This is known as overdiagnosis.
17 hours ago
0
34
Zidesamtinib demonstrates 93% response rate in ROS1-positive lung cancer
New results from the global phase 1/2 ARROS-1 trial showed clinically meaningful activity with zidesamtinib in patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who had not previously received ...
15 hours ago
0
6
Amivantamab-chemotherapy demonstrates longest overall survival reported for lung cancer with EGFR mutation
Results from the phase 3 PAPILLON study show that first-line amivantamab plus carboplatin-pemetrexed (amivantamab-chemotherapy) was associated with numerically longer overall survival compared with chemotherapy in patients ...
15 hours ago
0
4
First-line trastuzumab deruxtecan significantly improves progression-free survival in HER2-mutant lung cancer
First-line treatment with trastuzumab deruxtecan (T-DXd) significantly improved progression-free survival compared with pembrolizumab plus platinum-based chemotherapy in patients with advanced or metastatic HER2-mutant non-small ...
15 hours ago
0
3
Update shows sustained overall survival benefit with adjuvant osimertinib in resected EGFR-mutated lung cancer
An exploratory 8-year landmark update from the Phase III ADAURA trial showed that adjuvant osimertinib continued to provide a long-term overall survival benefit for patients with completely resected, EGFR-mutated stage IB–IIIA ...
15 hours ago
0
3
Zipalertinib plus chemotherapy significantly extends progression-free survival in first-line EGFR lung cancer
Adding zipalertinib to platinum-pemetrexed chemotherapy significantly improved progression-free survival in patients receiving first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion ...
15 hours ago
0
5
AI virtual cell uses protein dynamics to predict personalized breast cancer treatments
Not all cancer cells are the same, and neither are their responses to drugs. Finding the right drug for the right cancer cell is a long battle in drug development and in designing effective treatments. A new AI tool called ...
Ivonescimab significantly improves overall survival versus pembrolizumab in advanced lung cancer
Ivonescimab significantly prolonged overall survival compared with pembrolizumab as first-line treatment for patients with PD-L1-positive advanced non-small cell lung cancer (NSCLC), according to a prespecified interim analysis ...
Sep 12, 2026
0
12
Trial supports MRI surveillance over preventive brain radiation in small-cell lung cancer
Results from the international phase 3 SWOG S1827 MAVERICK trial show that brain MRI surveillance alone improved cognitive failure-free survival compared with MRI surveillance plus prophylactic cranial irradiation (PCI) in ...
Sep 12, 2026
0
7
Trial shows risvutatug rezetecan significantly improves overall survival in relapsed small-cell lung cancer
Results from the randomized Phase III ARTEMIS-008 trial show that risvutatug rezetecan (Ris-Rez), a B7-H3-directed antibody-drug conjugate, significantly improved overall survival compared with topotecan in patients with ...
Sep 12, 2026
0
7
Combination therapy does not meet primary endpoints in first-line PD-L1-high metastatic non-small cell lung cancer
Sacituzumab govitecan (SG) plus pembrolizumab did not demonstrate a statistically significant improvement in progression-free survival compared with pembrolizumab alone as first-line treatment for patients with metastatic ...
Sep 12, 2026
0
7
Tam-Peli extends survival by nearly four months in relapsed small-cell lung cancer
The phase 3 TAISHAN-302 trial found that tambotatug pelitecan (Tam-Peli, YL201), a novel anti-B7-H3 antibody-drug conjugate, significantly improved overall survival, progression-free survival and objective response rate compared ...
Sep 12, 2026
0
4
Subcutaneous tarlatamab shows favorable safety profile and antitumor activity in extensive-stage small cell lung cancer
Subcutaneous administration of tarlatamab was well tolerated and demonstrated preliminary antitumor activity in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC), according to findings from ...
Sep 12, 2026
0
6
Extended-interval tarlatamab dosing shows consistent activity and safety in previously treated small cell lung cancer
Extended-interval dosing regimens of tarlatamab demonstrated efficacy, safety and pharmacokinetic profiles generally consistent with the established every-two-week regimen in patients with previously treated small cell lung ...
Sep 12, 2026
0
18
Pumitamig plus elfetabart drozuntecan shows encouraging early activity in small cell lung cancer
The investigational combination of pumitamig and elfetabart drozuntecan (elfe-D) demonstrated a manageable safety profile and encouraging early antitumor activity in patients with small cell lung cancer (SCLC), according ...
Sep 12, 2026
0
14
Investigational EGFR x HER3 therapy supports Phase III dose after lung cancer trial
An investigational EGFR x HER3 antibody-drug conjugate demonstrated promising efficacy with a tolerable safety profile in patients with previously treated EGFR-mutated non-small cell lung cancer (NSCLC), supporting selection ...
Sep 12, 2026
0
12
Perioperative atezolizumab + chemotherapy more than doubles event-free survival in resectable stage II–IIIB NSCLC
Patients with resectable stage II–IIIB non-small cell lung cancer (NSCLC) treated with perioperative atezolizumab plus platinum-based chemotherapy experienced a median event-free survival of 62.8 months compared with 34.9 ...
Sep 12, 2026
0
10
Local consolidative therapy does not improve survival after dual immunotherapy in metastatic NSCLC
Adding local consolidative therapy (LCT) after induction treatment with nivolumab plus ipilimumab did not improve overall survival or progression-free survival in patients with metastatic non-small cell lung cancer (NSCLC), ...
Sep 12, 2026
0
8
Drinking very hot tea and coffee is linked to a greater risk of esophageal cancer
That morning brew may be doing you more harm than good. A study of almost 1 million tea and coffee drinkers has linked very hot drinks to a threefold greater risk of developing one type of esophageal cancer.
New 'smart' nanoparticles help the immune system better attack tumors
Adelaide University researchers have developed a new way to use mRNA technology to reprogram tumor-supporting immune cells and strengthen the body's anticancer immune response.
Sep 11, 2026
0
45
New findings link obesity to loss of natural breast cancer protection
A research team at Huntsman Cancer Institute at the University of Utah (the U) has found that obesity prevents a biological process that kills cancerous cells, revealing a possible reason obesity is a risk factor for breast ...
Sep 11, 2026
0
39
First-in-human study attacks inoperable pancreatic tumors with laser light
UCI Health, the clinical enterprise of the University of California, Irvine, is conducting a first-in-human, Phase I clinical trial using laser light to target localized but inoperable pancreatic tumors to help patients become ...
Sep 11, 2026
0
10
